Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | C1R | P00736 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30956246 | 0.79 | ADORA2A (0.59) | ADORA2AALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL10903923 | 0.79 | ADORA2A (0.59) | ADORA2AALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL4417855 | 0.79 | DPP4 (0.76) | DPP4CYP1A2CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL6223729 | 0.77 | ALDH1A1 (0.67) | ADORA2AALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL28619071 | 0.76 | ADORA2A (0.51) | ADORA2AALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL6220647 | 0.76 | DPP4 (0.59) | DPP4ADORA2AKDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL4419602 | 0.73 | DPP4 (0.56) | DPP4ADORA2AALDH1A1CYP1A2KDM4E | |
| SCHEMBL27854357 | 0.73 | ADORA2A (0.56) | ADORA2AALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL2361373 | 0.73 | CYP1A2 (0.65) | ADORA2AALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL4423802 | 0.72 | DPP4 (1.00) | DPP4CYP3A4CYP2C19ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4216197-B2 | — | — | 2009-01-28 | — | — | JP | claimed |
| EP-1476429-B1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | claimed |
| JP-2005526034-A | — | — | 2005-09-02 | — | — | JP | claimed |
| EP-1476429-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | claimed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | claimed |
| US-6800650-B2 | FOR THERAPY AND PROPHYLAXIS OF DIABETES, PARTICULARLY NON-INSULIN DEPENDENT DIABETES MELLITUS AND IMPAIRED GLUCOSE TOLERANCE. | HOFFMANN-LA ROCHE INC. | 2004-10-05 | — | — | US | claimed |
| US-20030195188-A1 | Pyridine and quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-16 | — | — | US | claimed |
| WO-2003068748-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | claimed |
| EP-1476429-B1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| EP-1476429-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-6800650-B2 | FOR THERAPY AND PROPHYLAXIS OF DIABETES, PARTICULARLY NON-INSULIN DEPENDENT DIABETES MELLITUS AND IMPAIRED GLUCOSE TOLERANCE. | HOFFMANN-LA ROCHE INC. | 2004-10-05 | — | — | US | disclosed |
| US-20030195188-A1 | Pyridine and quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-16 | — | — | US | disclosed |
| WO-2003068748-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195188-A1 | Pyridine and quinoline derivatives | DPP4, DPP3, DPP7 | DPP4 1/4885ADORA2A 1745/4885ALDH1A1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.